Showing posts with label Breast. Show all posts
Showing posts with label Breast. Show all posts

Tuesday, October 23, 2012

Breakthrough technique images breast tumors in 3-D with great clarity, reduced radiation

ScienceDaily (Oct. 22, 2012) — Like cleaning the lenses of a foggy pair of glasses, scientists are now able to use a technique developed by UCLA researchers and their European colleagues to produce three-dimensional images of breast tissue that are two to three times sharper than those made using current CT scanners at hospitals. The technique also uses a lower dose of X-ray radiation than a mammogram.

These higher-quality images could allow breast tumors to be detected earlier and with much greater accuracy. One in eight women in the United States will be diagnosed with breast cancer during her lifetime.

The research is published the week of Oct. 22 in the early edition of the Proceedings of the National Academy of Sciences.

The most common breast cancer screening method used today is called dual-view digital mammography, but it isn't always successful in identifying tumors, said Jianwei (John) Miao, a UCLA professor of physics and astronomy and researcher with the California NanoSystems Institute at UCLA.

"While commonly used, the limitation is that it provides only two images of the breast tissue, which can explain why 10 to 20 percent of breast tumors are not detectable on mammograms," Miao said. "A three-dimensional view of the breast can be generated by a CT scan, but this is not frequently used clinically, as it requires a larger dose of radiation than a mammogram. It is very important to keep the dose low to prevent damage to this sensitive tissue during screening."

Recognizing these limitations, the scientists went in a new direction. In collaboration with the European Synchrotron Radiation Facility in France and Germany's Ludwig Maximilians University, Miao's international colleagues used a special detection method known as phase contrast tomography to X-ray a human breast from multiple angles.

They then applied equally sloped tomography, or EST -- a breakthrough computing algorithm developed by Miao's UCLA team that enables high-quality image-reconstruction -- to 512 of these images to produce 3-D images of the breast at a higher resolution than ever before. The process required less radiation than a mammogram.

In a blind evaluation, five independent radiologists from Ludwig Maximilians University ranked these images as having a higher sharpness, contrast and overall image quality than 3-D images of breast tissue created using other standard methods.

"Even small details of the breast tumor can be seen using this technique," said Maximilian Reiser, director of the radiology department at Ludwig Maximilians University, who contributed his medical expertise to the research.

The technology commonly used today for mammograms or imaging a patient's bones measures the difference in an X-ray's intensity before and after it passes through the body. But the phase contrast X-ray tomography used in this study measures the difference in the way an X-ray oscillates through normal tissue rather than through slightly denser tissue like a tumor or bone. While a very small breast tumor might not absorb many X-rays, the way it changes the oscillation of an X-ray can be quite large, Miao said. Phase contrast tomography captures this difference in oscillation, and each image made using this technique contributes to the overall 3-D picture.

The computational algorithm EST developed by Miao's UCLA team is a primary driver of this advance. Three-dimensional reconstructions, like the ones created in this research, are produced using sophisticated software and a powerful computer to combine many images into one 3-D image, much like various slices of an orange can be combined to form the whole. By rethinking the mathematic equations of the software in use today, Miao's group developed a more powerful algorithm that requires fewer "slices" to get a clearer overall 3-D picture.

"The technology used in mammogram screenings has been around for more than 100 years," said Paola Coan, a professor of X-ray imaging at Ludwig Maximilians University. "We want to see the difference between healthy tissue and the cancer using X-rays, and that difference can be very difficult to see, particularly in the breast, using standard techniques. The idea we used here was to combine phase contrast tomography with EST, and this combination is what gave us much higher quality 3-D images than ever before."

While this new technology is like a key in a lock, the door will only swing open -- bringing high-resolution 3-D imaging from the synchrotron facility to the clinic -- with further technological advances, said Alberto Bravin, managing physicist of the biomedical research laboratory at the European Synchrotron Radiation Facility. He added that the technology is still in the research phase and will not be available to patients for some time.

"A high-quality X-ray source is an absolute requirement for this technique," Bravin said. "While we can demonstrate the power of our technology, the X-ray source must come from a small enough device for it to become commonly used for breast cancer screening. Many research groups are actively working to develop this smaller X-ray source. Once this hurdle is cleared, our research is poised to make a big impact on society."

These results represent the collaborative efforts of senior authors Miao, Bravin and Coan. Significant contributions were provided by co-first authors Yunzhe Zhao, a recent UCLA doctoral graduate in Miao's laboratory, and Emmanuel Brun, a scientist working with Bravin and Coan. Other co-authors included Zhifeng Huang of UCLA and Aniko Sztrókay, Paul Claude Diemoz, Susanne Liebhardt, Alberto Mittone and Sergei Gasilov of Ludwig Maximilians University.

The research was funded by UC Discovery/Tomosoft Technologies; the National Institute of General Medical Sciences, a division of the National Institutes of Health; and the Deutsche Forschungsgemeinschaft-Cluster of Excellence Munich-Centre for Advanced Photonics.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by University of California - Los Angeles. The original article was written by Melody Pupols.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Yunzhe Zhao, Emmanuel Brun, Paola Coan, Zhifeng Huang, Aniko Sztrókay, Paul Claude Diemoz, Susanne Liebhardt, Alberto Mittone, Sergei Gasilov, Jianwei Miao, and Alberto Bravin. High-resolution, low-dose phase contrast X-ray tomography for 3D diagnosis of human breast cancers. Proceedings of the National Academy of Sciences, 2012; DOI: 10.1073/pnas.1204460109

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Sunday, October 21, 2012

Developed a technology that predicts metastasis in breast cancer

ScienceDaily (Oct. 18, 2012) — Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) and The Institute of Photonic Sciences (ICFO) have collaborated on the development of a diagnostic tool that identifies the metastatic ability of breast cancer cells. The analysis is based on the characterization of the lipid component of the cells, which is indicative of malignancy. This has allowed the researchers to develop a classifier to discriminate cells capable of inducing metastasis.

The results of the study have been published in the online version of the scientific journal PLoS ONE.

The characterization of the lipids associated with malignancy has been possible thanks to the technological development of a spectroscopic device named Raman along with the versatility offered by the experimental models of breast cancer. The results of this process form the basis for introducing this technique in routine cytological diagnosis, which could be extended in the future to diagnose other tumours.

The researchers have analyzed the main components and, partly, the less discriminating ones to assess the profile of the lipid composition of breast cancer cells. They have generated a classification model that segregated metastatic and non-metastatic cells. "The algorithm for the discrimination of the metastatic ability is a first step towards the stratification of breast cancer cells using this quick and reactive tool," explains the study coordinator, Àngels Sierra, researcher at the Biological Clues of the Invasive and Metastatic Phenotype group of IDIBELL.

Using cytology techniques, the researchers have found a correlation between the activation of lipogenesis (the chemical reaction leading to fatty acids in an organism) and the amount of saturated fats in metastatic cells indicating a worse prognosis and a decreased survival. The lipid content of the breast cancer cells might be a useful measure to determine various functions coupled to the progression of breast cancer. The work has been supported by the Instituto de Salud Carlos III, the former Spanish Ministry of Science and Innovation and the private Cellex Barcelona Foundation.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by IDIBELL-Bellvitge Biomedical Research Institute.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Claudia Nieva, Monica Marro, Naiara Santana-Codina, Satish Rao, Dmitri Petrov, Angels Sierra. The Lipid Phenotype of Breast Cancer Cells Characterized by Raman Microspectroscopy: Towards a Stratification of Malignancy. PLoS ONE, 2012; 7 (10): e46456 DOI: 10.1371/journal.pone.0046456

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Blood hormone levels predicted long-term breast cancer risk for postmenopausal women

ScienceDaily (Oct. 18, 2012) — Blood hormone tests predicted a woman's risk for developing postmenopausal breast cancer for up to 20 years, according to data from the Nurses' Health Study presented at the 11th Annual AACR International Conference on Frontiers in Cancer Prevention Research, held in Anaheim, Calif., Oct. 16-19, 2012.

"We found that a single hormone level was associated with breast cancer risk for at least 16 to 20 years among postmenopausal women not using postmenopausal hormones," said Xuehong Zhang, M.D., an epidemiologist at Brigham and Women's Hospital and an instructor in medicine at Harvard Medical School in Boston, Mass. "We, and others, are now evaluating if the addition of hormone levels to current risk prediction models can substantially improve our ability to identify high-risk women who would benefit from enhanced screening or chemoprevention. If so, the current data suggest that hormone levels would not need to be measured in the clinic more than once every 10, or possibly 20, years."

Zhang and colleagues analyzed 796 patients with postmenopausal breast cancer who had not received hormone therapy. They conducted blood hormone tests at two time points: between 1989 and 1990, and between 2000 and 2002. They then matched each patient with two controls who were not diagnosed with breast cancer.

Women with hormone levels in the highest 25 percent for estradiol, testosterone and dehydroepiandrosterone sulfate (DHEAS) had a 50 percent to 107 percent greater chance for developing breast cancer compared with women in the lowest 25 percent. Relative risks for developing breast cancer were similar at one to 10 years versus 11 to 20 years (also 16 to 20 years) after blood collection.

Zhang and colleagues also investigated whether these higher hormone levels were more closely linked to hormone receptor- (HR) positive breast cancers and if they predicted risk regardless of tumor aggressiveness.

In the first case, they found that elevated levels of estradiol increased a woman's risk for HR-positive breast cancer. In general, increased hormone levels, except for DHEAS, tracked closely with increased risk for HR-positive breast cancer. Data on HR-negative cancers were inconclusive.

Elevated hormone levels were also associated with aggressive breast cancer, which the study defined as recurrent or fatal cancer. "The relationship was comparable or possibly stronger for recurrent and fatal breast cancer than it was for overall breast cancer risk, although these results were based on relatively small numbers of participants," said Zhang.

Researchers also confirmed the protective effect of sex hormone-binding globulin (SHBG), which seems to negate the cancer-causing effects of certain hormones. Women in the highest 25 percent of SHBG levels had a 30 percent lower risk for breast cancer compared with women in the lowest 25 percent for SHBG levels.

Zhang noted that the study had low case numbers for several cancer subgroups, including HER2-positive, triple-negative and basal-like breast cancers. More research is necessary to determine the relationship between elevated hormone levels and these important breast cancer subtypes.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by American Association for Cancer Research (AACR), via Newswise.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Blood Test May Help Define Breast Cancer Risk in Older Women

By Barbara Bronson Gray
HealthDay Reporter

THURSDAY, Oct. 18 (HealthDay News) -- The effort to develop a blood test to reveal a woman's risk for breast cancer may be one step closer to fruition, but is still far from becoming a reality, according to a new study.

The researchers found that blood hormone tests may predict the risk for developing postmenopausal breast cancer up to 20 years after a blood sample was taken.

But the study has limitations and needs to be replicated and expanded, said Dr. Xuehong Zhang, lead author and an epidemiologist at Brigham and Women's Hospital in Boston.

If the research is confirmed by other studies, women could have their blood levels of so-called "sex hormones" such as estradiol, testosterone and the androgen DHEAS (dehydroepiandrosterone sulfate) assessed every 10 to 20 years to get a biological assessment of their breast cancer risk, Zhang explained.

"We're thinking that the addition of hormone levels to our current risk prediction models might improve our ability to find high-risk women who would benefit from additional screening or prevention," he said.

The research was scheduled for presentation Thursday at the annual cancer prevention conference of the American Association for Cancer Research (AACR) in Anaheim, Calif.

Although it has been established that levels of estrogen and androgen in the blood can be associated with the risk of postmenopausal breast cancer, researchers haven't known how far into the future that risk prediction might go, Zhang said.

Working with participants in the Nurses' Health Study, a large and long-running effort to study women's health issues, blood samples were collected in 1989 to 1990, and then again in 2000 to 2002. Only postmenopausal women not taking hormones were eligible for this study. The researchers found 796 cases of diagnosed breast cancer through June 2010.

The study showed that women with hormone levels in the top quarter for estradiol, testosterone and DHEAS had a 50 percent to 107 percent greater chance of developing breast cancer as compared to women in the lowest quarter. Elevated hormone levels were also associated with recurrent or fatal breast cancer.

Those women in the highest quarter for sex hormone-binding globulin (SHBG) -- which has been understood to reduce the cancer-causing effects of some hormones -- had a 30 percent lower risk for breast cancer compared to those with SHBG levels in the lowest quarter.

The researchers also found that elevated levels of estrogen increased a woman's risk for hormone receptor-positive breast cancer.

Tests for the levels of these hormones are available now, but the results are often uncertain because laboratories vary greatly in how they define and interpret the results, Zhang said.

A breast cancer expert urged caution in interpreting the study.

"I would ask, if you're postmenopausal and have elevated levels of these hormones, should you potentially turn off your body's hormones [to help prevent breast cancer]?" asked Dr. Julie Gralow, director of breast medical oncology at the Seattle Cancer Care Alliance.

"If the hormones are good for your bones, your heart and maybe the brain, should you do anything to reduce them if you're perceived to be at some increased risk? It could affect your health negatively [to try to reduce those hormone levels]," Gralow said.

Should such a blood test become available, Gralow said she would want women to balance their potential risk of breast cancer against the danger of other diseases and conditions, including osteoporosis and fractures, heart disease and even dementia. "This is an interesting finding that needs to be put into the perspective of the total health of the postmenopausal woman," she said.

Risk factors for breast cancer currently include aging, genetics, race and ethnicity, family history and a personal history of breast cancer, among others, according to the American Cancer Association.

Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until they are published in a peer-reviewed journal.

MedicalNewsCopyright © 2012 HealthDay. All rights reserved. SOURCES: Xuehong Zhang, M.D., epidemiologist, Brigham and Women's Hospital, and instructor in medicine, Harvard Medical School, Boston; Julie Gralow, M.D., director, breast medical oncology, Seattle Cancer Care Alliance and professor, medical oncology division, University of Washington School of Medicine, Seattle; Oct. 18, 2012, presentation, American Association for Cancer Research cancer prevention conference, Anaheim, Calif.



View the original article here

Breast-Feeding Might Cut Risk for Tough-to-Treat Breast Cancer: Study

THURSDAY, Oct. 18 (HealthDay News) -- Breast-feeding may reduce a woman's risk for a form of breast cancer that's particularly difficult to treat, a new study suggests.

The study, by researchers at Columbia University, found that breast-feeding lowered the odds for estrogen receptor-negative and progesterone receptor-negative (ER/PR-) breast cancer.

These types of tumors have cells that do not carry a protein on their surface that binds to the hormones estrogen or progesterone. This means that they cannot be treated with standard hormone-based therapies.

Since there are few modifiable factors for ER/PR-negative breast cancers, the researchers concluded that women at risk for this type of tumor should be encouraged to breast-feed.

The study is scheduled to be presented Thursday at the annual cancer prevention conference of the American Association for Cancer Research (AACR) in Anaheim, Calif.

"We found an increased risk for estrogen receptor- and progesterone receptor-negative breast cancer in women who do not breast-feed, but in women who have children and breast-feed, there is no increased risk," study co-author Meghan Work, a doctoral student in the department of epidemiology at Columbia's Mailman School of Public Health in New York City, said in an AACR news release.

Still, one expert said the findings must be interpreted with caution.

"This was an observational study, and a causal relationship between breast-feeding and the decreased incidence of hormone-negative breast cancer is not established," stressed Dr. Alyssa Gillego, from the department of breast surgical oncology at Beth Israel Comprehensive Cancer Center, in New York City.

The study involved more than 4,000 women with breast cancer and almost 3,000 women without cancer. The researchers used data from the Breast Cancer Family Registry to examine the link between ER/PR-negative breast cancer and women's reproductive risk factors, such as the number of children they delivered and whether or not they breast-fed or took oral contraceptives.

The study found that having three or more children but not breast-feeding was linked to an increased risk ER/PR-negative breast cancer.

"Women who had children but did not breast-feed had about 1.5 times the risk for ER/PR-negative breast cancer when compared with a control population. If women breast-fed their children, there was no increased risk for ER/PR-negative cancer," Work noted. "This is particularly important as breast-feeding is a modifiable factor that can be promoted and supported through health policy."

They study also revealed that use of oral contraceptives made after 1975 was not associated with an increased risk for ER/PR-negative cancer risk.

Another specialist added, however, that there is a plausible explanation for a connection between breast-feeding and breast-cancer.

"Obviously, the breasts are meant to serve as an organ that produces milk for a newborn," explained Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital, in New York City. "Breasts are in an immature state until one's first pregnancy. Theoretically, if left in the immature state, breasts are not developing in the manner that nature intended. This altering of what nature intended may be the reason why women that do not breast-feed have a higher rate of cancer."

There could be other factors, she added. "The lowered risk might also be due to exposure or withdrawal of hormones as one nurses an infant," Bernik reasoned. "More study needs to be directed to finding out why nursing is protective, as this might lead to new methods of preventing breast cancer development."

Findings presented at medical meetings are typically considered preliminary until published in a peer-reviewed journal.

-- Mary Elizabeth Dallas MedicalNewsCopyright © 2012 HealthDay. All rights reserved. SOURCES: Alyssa Gillego, M.D., department of breast surgical oncology, Beth Israel Comprehensive Cancer Center, New York City; Stephanie Bernik, M.D,, chief of surgical oncology, Lenox Hill Hospital, New York City; American Association for Cancer Research, news release, Oct. 18, 2012



View the original article here

Friday, October 19, 2012

New insights into how genetic differences influence breast cancer risk from low-dose radiation

ScienceDaily (Oct. 16, 2012) — Scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory (Berkeley Lab) have identified tissue mechanisms that may influence a woman's susceptibility or resistance to breast cancer after exposure to low-dose ionizing radiation, such as the levels used in full-body CT scans and radiotherapy.

The research could lead to new ways to identify women who have higher or lower risks of breast cancer from low-dose radiation. Such a predictive tool could help guide the treatment of cancer patients who may be better served by non-radiation therapies.

The findings also support the idea that a person's genes play a big role in determining her risk of breast cancer from low-dose radiation. The current model for predicting cancer risk from ionizing radiation holds that risk is directly proportional to dose. But there's a growing understanding that this linear relationship doesn't apply at lower doses. Instead, the health effects of low-dose radiation may vary substantially among people depending on their genetic makeup.

The scientists, led by Andy Wyrobek of Berkeley Lab's Life Sciences Division, report their research October 15 in the journal PLOS ONE.

They studied mammary tissue from two strains of mice -- one that is susceptible to radiation-induced mammary gland cancer and one that is resistant -- before and after the mice were exposed to low-dose radiation.

The team then looked for differences between the two strains in how their genes turn on and off. They used a method that scans thousands of genes simultaneously. They found differences in genes that regulate tissue stress response, DNA repair, immune response, cellular proliferation, and other cellular and tissue mechanisms.

They also found that these differences carried over to breast cancer survivability in women. Breast cancer patients with gene expression profiles like the cancer-resistant mice (before radiation exposure) were more likely to survive eight years after diagnosis. Women with gene expression profiles like the cancer-sensitive mice were less likely to survive after eight years.

Based on this, the scientists believe the cellular and tissue mechanisms that control mice's risk of mammary gland cancer from low-dose radiation are similar to the mechanisms that affect a woman's chance of surviving breast cancer.

"Our studies of genetic differences in radiation sensitivity in mice, and individual variation in breast cancer survival in women, suggest that there are women who, because of their genes, have a higher risk of breast cancer when they're exposed to low-dose radiation," says Andy Wyrobek, who conducted the research with Antoine Snijders, Joe Gray, and several other Berkeley Lab scientists.

"This raises the possibility that we can use gene expression profiles to develop simple tests that screen for women who may be sensitive to low-dose radiation versus women who are resistant," Snijders says.

The scientists first studied mice before radiation exposure. They found more than 130 genes that express differently in blood and mammary tissue samples of cancer-resistant mice compared to cancer-sensitive mice.

To determine if these differences also apply to people, the scientists mined human breast cancer "knowledge bases" that link the expression of patients' tumor genes with their survival outcomes. They studied newly diagnosed women before they received radiation or chemical therapies. Women with gene expression levels like those of radiation-sensitive mice were less likely to survive after eight years. In contrast, women with expression levels like those of the resistant strain were more likely to survive the eight-year duration of the follow-up.

Next, gene expression analyses conducted a few hours after the end of low-dose exposure found changes in many genes in the mammary tissue of cancer-sensitive mice. Large numbers of genes that regulate their immune system were suppressed, while genes that regulate pubertal mammary gland development were turned on in error. In cancer-resistant mice, these genes showed only a small change in activity.

Analyses conducted one month after exposure yielded striking differences in the expression of a large set of genes that control cell proliferation. The cancer-sensitive mice had up-regulated many genes associated with cell division and cell renewal. The cancer-resistant mice had down-regulated these same genes below normal levels, which suggests they were able to activate tissue mechanisms that prevent cellular proliferation that can lead to cancer.

These differences again carried over to people. Breast cancer patients whose cell division and renewal genes were up-regulated like the cancer-sensitive mice didn't survive as long as patients in which the same genes were suppressed.

The scientists are now refining these gene expression signatures by studying large groups of women with breast cancer. They're also testing the mechanisms by which these signatures control radiation sensitivity using special breast cell culture models developed at Berkeley Lab.

"This research opens promising opportunities for developing blood tests that predict a woman's risk for breast cancer, and which identify women who are susceptible to the cancer effects of low-dose radiation exposures," says Wyrobek.

This research was supported by Berkeley Lab's Laboratory Directed Research and Development fund and the Department of Energy's Office of Science.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by DOE/Lawrence Berkeley National Laboratory.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Antoine M. Snijders, Francesco Marchetti, Sandhya Bhatnagar, Nadire Duru, Ju Han, Zhi Hu, Jian-Hua Mao, Joe W. Gray, Andrew J. Wyrobek. Genetic Differences in Transcript Responses to Low-Dose Ionizing Radiation Identify Tissue Functions Associated with Breast Cancer Susceptibility. PLoS ONE, 2012; 7 (10): e45394 DOI: 10.1371/journal.pone.0045394

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Epigenetic difference in twins explains different risk of breast cancer

ScienceDaily (Oct. 17, 2012) — It can be detected an epigenetic alteration associated with an increased risk of breast cancer in the sick twin a few years before the clinical diagnosis.

Monozygotic twins have the same genome, that is, the same DNA molecule in both siblings. Despite being genetically identical, both twins may have different diseases at different times. This phenomenon is called "twin discordance." But how can people who have the same genetic sequence present different pathologies and at different ages? The explanation partly lies in the fact that the chemical signals added in the DNA to "switch off" or "switch on" genes can be different. These signals are known as epigenetic marks.

The research team led by Manel Esteller, director of the Cancer Epigenetics and Biology Program at the Bellvitge Biomedical Research Institute (IDIBELL), Professor of Genetics at the University of Barcelona and ICREA researcher, has identified an epigenetic change in the twin who will develop breast cancer but not in the healthy one. The finding has been advanced this week in the journal Carcinogenesis.

The research group led by Dr. Esteller studied the levels of DNA methylation (the best known epigenetic mark) in the blood of 36 pairs of twins diagnosed with breast cancer or healthy. Researchers analyzed half a million pieces of the genome in each twin and compared them with each other, and they found that women who have developed breast tumours showed a pathological gain of methylation in the DOK7 gene. " an epigenetic alteration associated with an increased risk of breast cancer can be detected in the sick twin a few years before the clinical diagnosis," said Dr. Esteller about the research results.

The next step for the researchers will be knowing the exact function of the DOK7 gene. "We believe it is a regulator of tyrosine kinases, an antitumor drug target already used for the treatment of breast cancer. If DOK7 performs this function, new studies to test drugs with tumour chemopreventive effects in breast cancer could be planned in the future," concludes the research coordinator.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by IDIBELL-Bellvitge Biomedical Research Institute.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Journal Reference:

Heyn H, Carmona FJ, Gomez A, Ferreira HJ, Bell JT, Sayols S, Ward K, Stefansson OA, Moran S, Sandoval J, Eyfjord JE, Spector TD, Esteller M. DNA methylation profiling in breast cancer discordant identical twins identifies DOK7 as novel epigenetic biomarker. Carcinogenesis, 2012

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Vegetable-derived compound effective in treating triple-negative breast cancer, research suggests

ScienceDaily (Oct. 17, 2012) — A new compound created from a rich source in vegetables including broccoli and brussel sprouts has been developed to combat triple-negative breast cancer (TNBC). This research is being presented at the 2012 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, the world's largest pharmaceutical sciences meeting, in Chicago, Ill., on Oct. 14 -- 18, during Breast Cancer Awareness Month.

TNBC accounts for approximately 15-20 percent of all breast cancer cases in the U.S. It is one of the most aggressive forms of breast cancer; it grows faster, spreads to other parts of the body earlier, is harder to detect on a mammogram and recurs more often.

Mandip Sachdeva, Ph.D. and Chandraiah Godugu, P.h.D. from Florida A&M University, in collaboration with Stephen Safe, Ph.D., from Texas A&M University, have evaluated the activity of novel C-substituted diindolylmethane (C-DIM) derivatives and demonstrated that they have superior anticancer activities. Sachdeva's study reveals that these synthetic compounds derived from diindolylmethane (DIM), commonly found in various types of cruciferous vegetables, can be used to treat several types of cancer, including triple-negative breast cancer. C-DIMs are also being investigated for their cancer prevention activity.

"Targeted treatment options for TNBC are limited; current treatments, such as infusions, result in poor patient compliance and increased toxicity," said Sachdeva. "We are confident that the compounds we are currently working with are an effective treatment for triple-negative breast cancer. These compounds are safer for the patient than current treatments available."

In contrast to existing anticancer drugs, the diindolylmethane compounds are orally active, so they could be available to patients in pill form and safe to take daily. When taken in combination with existing anticancer drugs, the diindolylmethane compounds can effectively decrease the number of treatments a patient receives.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Story Source:

The above story is reprinted from materials provided by American Association of Pharmaceutical Scientists, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.


View the original article here

Tuesday, October 16, 2012

Service That Speeds Up Breast Cancer Diagnosis Pays Off: Study

THURSDAY, Oct. 11 (HealthDay News) -- A type of service called "patient navigation" -- which helps people cope with an illness, deal with health insurance questions and schedule appointments -- may reduce delays in the detection of breast cancer, a new study has found.

Suspicious breast lumps were diagnosed nearly four times sooner when women were assisted by patient navigators, according to the study. The use of these patient navigation services could lead to an increase in the number of cancerous tumors that are diagnosed before they become more difficult to treat, the findings suggested.

"The time savings really paid off for the women in this study," study author Heather Hoffman, an associate professor of epidemiology and biostatistics at the George Washington University School of Public Health and Health Services, said in a university news release. "A quicker diagnosis of breast cancer often translates to faster treatment and might give women a better shot at survival."

The study included more than 2,600 women with a suspicious breast lump who were examined at one of nine hospitals or clinics in the Washington, D.C. area. About half of the women received navigation services, which helped them deal with a lack of insurance, child-care issues and other problems that might prevent them from scheduling a follow-up exam. Meanwhile, the rest of the women were only given standard advice to follow up on the lump that was found.

The researchers then calculated the amount of time that lapsed between when the suspicious lumps were found and when the women received a diagnosis.

The study revealed that patient navigation helped women receive their diagnosis much sooner. Women who received these services had an average diagnosis time of just 25 days, compared to 42 days for those who did not have access to a patient navigator.

In addition, among women who needed a biopsy, those who received help from a patient navigator got their diagnosis in about 27 days, vs. 58 days for those who did not get navigation services, the results showed.

The researchers noted that uninsured patients often have trouble finding a doctor willing to treat them. Yet, in the study, uninsured women who received navigation services were more likely to get a quicker diagnosis than uninsured women who didn't have the help of a patient navigator.

Delays in cancer diagnosis may lead to potentially dangerous delays in treatment. Complicating matters, Hoffman noted, women who find a lump in their breast are often overwhelmed by fear, which may prevent them from following up on their medical care as soon as possible.

"Navigators follow up with women and encourage them to go on for additional tests until they get an answer either one way or the other," said Hoffman. "With help, many women are able to move forward to get the care they need."

Each year in the United States, 40,000 women die due to breast cancer, and Washington, D.C. has one of the highest breast cancer death rates in the nation, the study authors pointed out in the news release. They suggested that more research is needed to determine if women in other cities and rural areas would also benefit from patient navigation services.

The study was published in the October issue of Cancer Epidemiology, Biomarkers & Prevention.

-- Mary Elizabeth Dallas MedicalNewsCopyright © 2012 HealthDay. All rights reserved. SOURCE: George Washington University, news release, Oct. 8, 2012



View the original article here

Twitter Delicious Facebook Digg Stumbleupon Favorites More

 
Design by Free WordPress Themes | Bloggerized by Lasantha - Premium Blogger Themes | Facebook Themes